News
-
-
-
COMMUNIQUÉ DE PRESSE
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome
Norgine's mavorixafor receives positive CHMP opinion for WHIM syndrome treatment in the EU. Final EC decision expected in Q2 2026. Partnership with X4 Pharmaceuticals